Casimersen is a Antisense Oligonucleotide owned by Sarepta Therapeutics, and is involved in 7 clinical trials, of which 3 were completed, and 4 are ongoing.

Casimersen is based on the exon skipping technology which skips exon 45 of the dystrophin gene, allowing for restoration of the reading frame in the mRNA sequence. By skipping this exon, a truncated, yet potentially functional form of the dystrophin protein is produced, which could ameliorate the disease process. The phosphorodiamidate morpholino oligomers (PMOs) are a distinct class of oligonucleotide analogs. They bind to RNA and efficiently interfere with gene expression in a sequence-specific manner.

The revenue for Casimersen is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Casimersen NPV Report.

Casimersen is originated and owned by Sarepta Therapeutics.

Casimersen Overview

Casimersen (Amondys 45) is an antisense oligonucleotide of phosphorodiamidate morpholino oligomer. It is formulated as injection solution for intravenous route of administration. Casimersen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

Casimersen (SRP-4045 or Exon 45 PMO) is under development for the treatment of Duchenne muscular dystrophy (DMD). It is administered as an intravenous infusion. It is a Phosphorodiamidate morpholino oligomer (PMO) that acts by targeting dystrophin DMD. The drug candidate is developed based on phosphorodiamidate morpholino oligomers (PMOs) technology and exon skipping technology which skips exon 45 of the dystrophin gene.

Sarepta Therapeutics Overview

Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53 and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-5051, SRP-9001, SRP-9003 and SRP-5045 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Sarepta is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$701.9 million for the fiscal year ended December 2021 (FY2021), an increase of 30% over FY2020. The operating loss of the company was US$362.2 million in FY2021, compared to an operating loss of US$456.1 million in FY2020. The net loss of the company was US$418.8 million in FY2021, compared to a net loss of US$554.1 million in FY2020. The company reported revenues of US$230.3 million for the third quarter ended September 2022, a decrease of 1.4% over the previous quarter.

Quick View – Casimersen

Report Segments
  • Innovator (NME)
Drug Name
  • Casimersen
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.